Health Care

2738 posts

Cancer fighter Theralase aims to turn lab wins into human trials

Theralase (TSXV:TLT) begins Good Laboratory Practice toxicology analysis of Rutherrin, its drug candidate to target and destroy cancer cells.

Restart Life Sciences serves up exponential revenue growth

Restart Life Sciences (CSE:HEAL) more than doubled revenue at stable profit margins in Q2 2026 amid several promising commercial activations.
The Market Online Video

NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing

NurExone CEO Dr. Lior Shaltiel discusses U.S. exosome manufacturing, Mexico expansion, ExoPTEN and plans for a potential U.S. listing.
The Market Online Video

Med-X targets global pest control market with Nature-Cide

Med-X CEO Matthew Mills discusses Nature-Cide, professional pest control partnerships, global expansion and the company’s planned Nasdaq listing.
  • Ricki Lee
  • 10 mins
  • 01 September 2026 04:00 (EDT)

The 5-Minute Investor Podcast, Ep. 76: Breaking down Curaleaf’s bid for Aurora Cannabis

Listen to episode 76 of The 5-Minute Investor Podcast, featuring analysis on cannabis stocks Curaleaf and Aurora.
The Market Online Video

AI-powered automation for the beauty and wellness industry

Yocale.ai CEO Aydin Asli discusses its AI platform, beauty and wellness strategy, C$1.74 million financing and acquisition plans.

Glow Lifetech keeps growth train rolling

Biotech and cannabis innovator Glow Lifetech (CSE:GLOW) posted its 12th consecutive quarter of year-over-year revenue growth in Q2 2026.

3 ambitious pharma stocks near commercialization

A concise look at Abivax, Q32 Bio and Achieve Life Sciences, three pharma stocks keen to solve some of healthcare's most vital unmet needs.

Heart disease continues to disproportionately affect underserved communities

Heart disease disproportionately affects Medicaid recipients, Medicare beneficiaries, rural residents, and lower-income populations.

Avricore and Abbott Labs sign UK pharmacy testing deal

Avricore Health (TSXV:AVCR) signs a multi-year agreement to supply and distribute Abbott Labs' point-of-care testing products in the UK.

The 5-Minute Investor Podcast, Ep. 74: Two top-returning stocks to watch

Check out episode 74 of The 5-Minute Investor Podcast, featuring analysis on top-returning stocks Sparc AI and Butterfly Network.

Cannabis microcap posts potent Q2 results

MediPharm Labs (TSX:LABS), a cannabis-focused pharma company, elevated into positive net income in Q2 2026.
Heart scans using Ventripoint Diagnostic's VMS+ technology

Ventripoint broadens access to AI cardiac imaging

Ventripoint (TSXV:VPT) is expanding access to its AI-powered cardiac imaging platform to help hospitals adopt the it without large costs.
Eli Lilly widens its lead over Novo Nordisk as demand for weight-loss drugs drives higher revenue

Weight-loss drug boom widens Lilly’s lead over Novo

Eli Lilly’s revenue surged 48 per cent as Mounjaro and Zepbound widened its commercial lead over rival Novo Nordisk.

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.

PharmaTher evaluating 3D printing for personalized peptide medicines

PharmaTher is out to evaluate its GMP-ready 3D printing platform for producing personalized peptide medicines with customized doses.

Why biotech is outpacing the AI slump: 3 stocks to watch

The biotech sector is outperforming the broader market, shining a light on stocks best-positioned to address unmet patient needs.

The 5-Minute Investor Podcast, Ep. 71: Weight-loss drug stocks

Listen to ep. 71 of The 5-Minute Investor Podcast, with analysis on weight-loss drug stocks Structure Therapeutics and Viking Therapeutics.